BioInvent International AB (publ)
BioInvent International AB (publ) (BOVNF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for BioInvent International AB (publ) (BOVNF), covering cash flow, earnings, and balance sheets.
BioInvent International AB (publ) (BOVNF) Income Statement & Financial Overview
View the income breakdown for BioInvent International AB (publ) BOVNF across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $21.37M | $12.76M | $4.61M | $5.94M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $21.37M | $12.76M | $4.61M | $5.94M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $129.29M | $107.47M | $138.59M | $82.38M |
| SG&A Expenses | $17.70M | $12.82M | $9.60M | $8.59M |
| Operating Expenses | $147.24M | $119.91M | $148.19M | $90.97M |
| Total Costs & Expenses | $147.24M | $119.91M | $153.07M | $95.69M |
| Interest Income | $0.00 | $9.93M | $0.00 | $11.80M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $4.88M | $4.83M | $4.88M | $4.71M |
| EBITDA | -$121.00M | -$102.31M | -$143.44M | -$85.008M |
| EBITDA Ratio | -$5.66 | -$8.02 | -$31.11 | -$14.31 |
| Operating Income | -$125.87M | -$107.15M | -$148.46M | -$89.74M |
| Operating Income Ratio | -$5.89 | -$8.39 | -$32.20 | -$15.10 |
| Other Income/Expenses (Net) | $9.04M | $9.93M | $11.04M | $11.80M |
| Income Before Tax | -$116.83M | -$97.21M | -$137.28M | -$77.92M |
| Income Before Tax Ratio | -$5.47 | -$7.62 | -$29.77 | -$13.11 |
| Income Tax Expense | $48000.00 | $28000.00 | $28000.00 | $31000.00 |
| Net Income | -$116.88M | -$97.24M | -$137.31M | -$77.95M |
| Net Income Ratio | -$5.47 | -$7.62 | -$29.78 | -$13.12 |
| EPS | -$1.78 | -$1.48 | -$2.09 | -$1.18 |
| Diluted EPS | -$1.78 | -$1.48 | -$2.09 | -$1.18 |
| Weighted Avg Shares Outstanding | $65.66M | $65.70M | $65.80M | $65.80M |
| Weighted Avg Shares Outstanding (Diluted) | $65.66M | $65.70M | $65.80M | $65.80M |
The company's financials show resilient growth, with revenue advancing from $5.94M in Q1 2024 to $21.37M in Q4 2024. Gross profit remained healthy with margins at 100% in Q4 2024 compared to 100% in Q1 2024. Operating income hit -$125.87M last quarter, sustaining a consistent -589% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$121.00M. Net income dropped to -$116.88M, while earnings per share reached -$1.78. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan